Drug & intervention
capivasertib
RxCUI 2669967
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
25 shownRash & Diarrhea Prophylaxis With CapivasertibNCT07426822 · 2026-08-15
RECRUITINGStudy of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsNCT07287917 · 2026-01-26
RECRUITINGPhase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentNCT07281833 · 2025-11-27
RECRUITINGPhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26
RECRUITINGCapivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerNCT06607757 · 2024-12-04
RECRUITINGA Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossNCT05593497 · 2024-05-31
RECRUITINGImmunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCNCT05720260 · 2023-01-17
RECRUITINGGenomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerNCT04812366 · 2021-09-21
RECRUITINGA Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy ParticipantsNCT07088913 · 2025-07-28
COMPLETEDEffect of Capivasertib on ctDNA in ER Positive Breast CancerNCT06613516 · 2025-02-01
WITHDRAWNA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainNCT06764186 · 2025-01-07
ACTIVE_NOT_RECRUITINGCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsNCT06635447 · 2024-09-26
ACTIVE_NOT_RECRUITINGOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerNCT05563220 · 2023-01-24
ACTIVE_NOT_RECRUITINGStudy of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT05348577 · 2022-03-25
ACTIVE_NOT_RECRUITINGCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)NCT04862663 · 2021-05-10
ACTIVE_NOT_RECRUITINGA Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the BodyNCT04712396 · 2021-02-01
COMPLETEDA Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerNCT04556773 · 2020-12-17
ACTIVE_NOT_RECRUITINGCapivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyNCT04493853 · 2020-07-13
ACTIVE_NOT_RECRUITINGCapivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerNCT04305496 · 2020-04-16
ACTIVE_NOT_RECRUITINGA Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerNCT04087174 · 2019-08-05
COMPLETEDCapivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCNCT03997123 · 2019-06-25
ACTIVE_NOT_RECRUITINGA Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerNCT03742102 · 2018-12-21
ACTIVE_NOT_RECRUITINGAMTEC IIT: Phase 2 Multiarm Study in TNBCNCT03801369 · 2018-12-12
TERMINATEDTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITINGmTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianNCT02208375 · 2014-11-11
ACTIVE_NOT_RECRUITINGConditions being studied
Breast Cancer5Metastatic Breast Cancer5Prostate Cancer3Advanced Breast Cancer2Locally Advanced (Inoperable) or Metastatic Breast Cancer2Recurrent Breast Carcinoma2Recurrent Ovarian Carcinoma2Triple Negative Breast Neoplasms2Advanced Lymphoma1Advanced Malignant Solid Neoplasm1Anatomic Stage IV Breast Cancer AJCC v81Bladder Carcinoma1BRCA1 Mutation Carrier1BRCA2 Mutation Carrier1Breast Carcinoma1CCCA Assessed by Ki67 Drop Below <2.7% From Baseline1Cervical Carcinoma1Colon Carcinoma1Colorectal Carcinoma1Endometrial Adenocarcinoma1
Research locations
Leading sponsors
AstraZeneca12Aminex Therapeutics, Inc.1GBG Forschungs GmbH1Gordon Mills, MD, PhD1Imperial College London1M.D. Anderson Cancer Center1Maryam Lustberg1National Cancer Institute (NCI)1National Taiwan University Hospital1Relay Therapeutics, Inc.1Stemline Therapeutics, Inc.1University of British Columbia1VA Office of Research and Development1Women's Cancer Study Group GmbH1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.